About Us
OncoSec Medical Inc (OMI) is an advanced-stage biomedical company focused on commercializing therapeutic oncology products. Founded in 2011, the company is committed to bringing patients new and improved treatment alternatives to existing therapies that have untoward side-effects and where improvements to the patient’s treatment and personal well-being are both desirable and achievable.
The basis for OMI’s core technology is a novel, enhanced delivery system using a form of cell membrane stimulation known as electroporation. Using this system to deliver a proven chemotherapy or an immunotherapy, these therapies can effectively treat cancerous tumors and cancerous cells in the predominantly healthy tissue around the tumor while reducing or eliminating detrimental treatment outcomes associated with other “standard of care” therapies such as surgery, chemotherapy and radiation.
The basis for OMI’s core technology is a novel, enhanced delivery system using a form of cell membrane stimulation known as electroporation. Using this system to deliver a proven chemotherapy or an immunotherapy, these therapies can effectively treat cancerous tumors and cancerous cells in the predominantly healthy tissue around the tumor while reducing or eliminating detrimental treatment outcomes associated with other “standard of care” therapies such as surgery, chemotherapy and radiation.
Oncology (from the Ancient Greek onkos (óγκος), meaning bulk, mass, or tumor, and the suffix -logy (λογια),
meaning "study of") is a branch of medicine that deals with tumors (cancer).
The science behind OMI's delivery technology, called the Oncology Medical System (OMS), is based on the application of brief electrical pulses to the cancer cells of various solid tumor types. The pulses create a temporary, reversible increase in the permeability of cells’ membranes, a process known as electroporation.
When a chemotherapeutic or immunotherapeutic agent is first locally injected into a selected tumor and surrounding tissue, the subsequent application of electroporation causes temporary pores in the cell membrane that allows significantly increased entry of these agents into the cell. The agents can then perform their intended function: the chemotherapeutic will kill rapidly dividing cells, i.e. cancerous cells; the immunotherapy will stimulate the body’s immune system in order to enhance its cancer-killing capabilities.
These new "electro-oncology" therapies can be selectively applied to specific parts of the body affected by a tumor(s). They can minimize or avoid the detrimental cosmetic and functional effects of surgery while reducing or eliminating the toxic side effects of chemotherapy and radiation.
OMI’s near-term development and commercialization goals are to seek marketing approval in Europe and initiate pivotal clinical trials in the US by 2012.
We are aim to create a new standard of care in oncology through our pioneering research and global development and our commitment to the highest standards of ethics and quality in all that we do. OncoSec is committed to enabling people with life-altering cancers to lead better lives through the development of our treatment approaches. We will measure our success by the patients we help.